Cephalon Inc. / CIMA Labs Inc.

Breakthrough Cancer Pain (BTCP)

Disease Overview

Breakthrough cancer pain refers to transient flares of severe pain that occur despite around-the-clock opioid analgesia in cancer patients. Fast-onset transmucosal fentanyl products were developed to address the rapid onset and short duration of these episodes, where oral opioids act too slowly.

Competitive Landscape

At the time of Cephalon's November 2003 merger agreement with CIMA Labs, Cephalon's Actiq (oral transmucosal fentanyl citrate lozenge) was the dominant branded BTCP product in the US, while CIMA was developing OraVescent fentanyl — a buccal effervescent tablet (later launched as Fentora in 2006) designed to deliver faster onset and greater bioavailability than the lozenge. The FTC required Cephalon to license a generic version of Actiq to Barr Laboratories to preserve competition, since the merger combined the only brand and the only late-stage competitor in BTCP fentanyl. The deal entrenched Cephalon's BTCP franchise ahead of Actiq's loss of exclusivity and gave it a next-generation life-cycle product. Subsequent BTCP entrants included Onsolis (BDSI/Meda), Subsys (Insys, sublingual fentanyl spray — later mired in DOJ litigation), Lazanda (nasal spray), and Abstral (sublingual tablet). Generic transmucosal fentanyl entry compressed pricing significantly post-2007, and the broader category became commercially constrained by escalating opioid scrutiny in the 2010s.